Clinical Trials Browser

INDUSTRY × aprutumab ixadotin × Clear all

NCT02368951 2017-07-12

Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

Phase 1 Terminated

Medical Oncology